Sign in or create an account to add this stock to your watchlist.
About Infinity Pharmaceuticals (NASDAQ:INFI)
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INFI
CUSIP45665G30
Phone617-453-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio10.81
Quick Ratio10.81
Price-To-Earnings
Trailing P/E Ratio-2.45
Forward P/E Ratio-2.74
P/E GrowthN/A
Sales & Book Value
Annual Sales$6 million
Price / Sales18.97
Cash FlowN/A
Price / CashN/A
Book Value$0.81 per share
Price / Book2.51
Profitability
EPS (Most Recent Fiscal Year)($0.83)
Net Income$-41,830,000.00
Net MarginsN/A
Return on Equity-79.47%
Return on Assets-61.73%
Miscellaneous
Employees22
Outstanding Shares56,070,000
Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions
What is Infinity Pharmaceuticals' stock symbol?
Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."
How were Infinity Pharmaceuticals' earnings last quarter?
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.18) by $0.00. View Infinity Pharmaceuticals' Earnings History.
Who are some of Infinity Pharmaceuticals' key competitors?
Some companies that are related to Infinity Pharmaceuticals include Zymeworks (ZYME), ProMetic Life Sciences (PFSCF), Dermira (DERM), Innate Pharma (IPHYF), Sinovac Biotech (SVA), Merus (MRUS), Clearside Biomedical (CLSD), Depomed (DEPO), GTX (GTXI), ArQule (ARQL), American Brivision (Holding) (ABVC), MediciNova (MNOV), Albireo (ALBO), Synergy Pharmaceuticals (SGYP) and Syros Pharmaceuticals (SYRS).
Who are Infinity Pharmaceuticals' key executives?
Infinity Pharmaceuticals' management team includes the folowing people:
- Ms. Adelene Q. Perkins, Chairman & CEO (Age 58)
- Dr. Lawrence E. Bloch M.D., J.D., Pres, Principal Accounting Officer & Treasurer (Age 52)
- Mr. Seth A. Tasker J.D., VP, Gen. Counsel & Sec. (Age 39)
- Ms. Melissa Hackel, VP of Fin.
- Dr. Jeffery L. Kutok M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 51)
Has Infinity Pharmaceuticals been receiving favorable news coverage?
Media stories about INFI stock have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a coverage optimism score of 0.18 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 47.20 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Infinity Pharmaceuticals' major shareholders?
Infinity Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BIOTECHNOLOGY VALUE FUND L P (21.70%), Dimensional Fund Advisors LP (1.31%), Wasatch Advisors Inc. (0.64%), Millennium Management LLC (0.58%), GSA Capital Partners LLP (0.54%) and Wells Fargo & Company MN (0.35%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Lawrence E Bloch, Michael C Venuti, Sujay Kango and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.
Which institutional investors are selling Infinity Pharmaceuticals stock?
Which institutional investors are buying Infinity Pharmaceuticals stock?
INFI stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Dimensional Fund Advisors LP, GSA Capital Partners LLP and Wells Fargo & Company MN. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Lawrence E Bloch and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.
How do I buy shares of Infinity Pharmaceuticals?
Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Infinity Pharmaceuticals' stock price today?
One share of INFI stock can currently be purchased for approximately $2.03.
How big of a company is Infinity Pharmaceuticals?
Infinity Pharmaceuticals has a market capitalization of $113.82 million and generates $6 million in revenue each year. The biotechnology company earns $-41,830,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 22 workers across the globe.
How can I contact Infinity Pharmaceuticals?
Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]
MarketBeat Community Rating for Infinity Pharmaceuticals (INFI)
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Infinity Pharmaceuticals (NASDAQ:INFI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Infinity Pharmaceuticals in the last 12 months. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Infinity Pharmaceuticals (NASDAQ:INFI) Consensus Price Target History
Infinity Pharmaceuticals (NASDAQ:INFI) Analyst Ratings History
Show:
(Data available from 5/25/2016 forward)
Infinity Pharmaceuticals (NASDAQ:INFI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Infinity Pharmaceuticals (NASDAQ INFI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 11.45%
Institutional Ownership Percentage: 50.55%
Infinity Pharmaceuticals (NASDAQ INFI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/10/2018 | Value Fund L P Biotechnology | Major Shareholder | Buy | 1,510,000 | $1.97 | $2,974,700.00 | |  |
| 3/5/2018 | Adelene Q Perkins | CEO | Sell | 5,000 | $2.78 | $13,900.00 | 607,252 | |
| 12/6/2017 | Lawrence E Bloch | President | Buy | 500,000 | $1.81 | $905,000.00 | 580,944 | |
| 10/4/2017 | Value Fund L P Biotechnology | Insider | Buy | 1,600,046 | $1.26 | $2,016,057.96 | | |
| 3/17/2017 | Michael C Venuti | Director | Sell | 6,250 | $3.48 | $21,750.00 | 50,000 | |
| 1/3/2017 | Value Fund L P Biotechnology | Major Shareholder | Buy | 4,379 | $1.34 | $5,867.86 | | |
| 12/30/2016 | Value Fund L P Biotechnology | Major Shareholder | Buy | 742,401 | $1.34 | $994,817.34 | | |
| 12/20/2016 | Value Fund L P Biotechnology | Major Shareholder | Buy | 654,921 | $1.31 | $857,946.51 | | |
| 12/13/2016 | Sujay Kango | Insider | Sell | 75,000 | $1.28 | $96,000.00 | 50,590 | |
| 12/12/2016 | Sujay Kango | Insider | Sell | 25,009 | $1.30 | $32,511.70 | 50,590 | |
| 12/2/2016 | Value Fund L P Biotechnology | Major Shareholder | Buy | 201,394 | $1.19 | $239,658.86 | | |
| 6/25/2015 | Adelene Q Perkins | CEO | Sell | 5,000 | $10.93 | $54,650.00 | | |
| 6/15/2015 | Vito J Palombella | Insider | Sell | 4,737 | $10.97 | $51,964.89 | | |
| 5/27/2015 | Adelene Q Perkins | CEO | Sell | 10,000 | $12.81 | $128,100.00 | | |
| 5/14/2015 | Adelene Q Perkins | CEO | Sell | 10,000 | $12.18 | $121,800.00 | | |
| 3/16/2015 | Adelene Q Perkins | CEO | Sell | 20,000 | $16.00 | $320,000.00 | | |
| 1/29/2015 | Adelene Q Perkins | CEO | Sell | 20,000 | $14.83 | $296,600.00 | | |
| 12/15/2014 | Vito J Palombella | Insider | Sell | 4,737 | $16.32 | $77,307.84 | | |
| 11/26/2014 | Vito J Palombella | Insider | Sell | 4,736 | $15.00 | $71,040.00 | | |
| 9/30/2014 | Anthony B Evnin | Director | Sell | 112,451 | $13.56 | $1,524,835.56 | | |
| 9/3/2014 | Vito J Palombella | Insider | Sell | 9,472 | $15.39 | $145,774.08 | | |
| 11/27/2013 | Anthony B Evnin | Director | Sell | 163,864 | $14.82 | $2,428,464.48 | | |
| 9/13/2013 | Adelene Perkins | CEO | Sell | 45,000 | $20.72 | $932,400.00 | 447,535 | |
| 6/20/2013 | Vito J Palombella | Insider | Sell | 23,150 | $18.53 | $428,969.50 | | |
| 11/26/2012 | Christopher M Lindblom | Insider | Sell | 13,885 | $25.73 | $357,261.05 | | |
| 9/7/2012 | Co Beacon | Major Shareholder | Buy | 5,416,565 | $14.50 | $78,540,192.50 | | |
(Data available from 1/1/2013 forward)
Infinity Pharmaceuticals (NASDAQ INFI) News Headlines
| Source: |
|
Infinity Pharmaceuticals (NASDAQ:INFI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Infinity Pharmaceuticals (NASDAQ:INFI) Income Statement, Balance Sheet and Cash Flow Statement
Infinity Pharmaceuticals (NASDAQ INFI) Stock Chart for Friday, May, 25, 2018
Loading chart…
